Vitamin E monotherapy has not been shown to reduce NASH fibrosis in 15 clinical RCTs but may have clinically meaningful improvements in NASH in monotherapy or in combination with vitamin C, spironolactone, or pioglitazone (PPAR-γ agonist) in RCTs [88,89,90,91,92]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.